Skip to main content
SpringerLink
Log in

Experimental specific immunotherapy

  • Chapter
Immunological Aspects of Cancer

Abstract

Specific cancer immunotherapy continues to excite the imagination of investigators with its promise of cure. However, the message coming from most trials that the tumour burden capable of destruction by the immune system is not large carries the implication that immunotherapy will find its place as an adjunct to other therapeutic modalities. Impetus for exploring combined modalities which include immunotherapy comes from the observation that immunological kill of cancer cells does not suffer from the theoretical limitation of first order kinetics as do radiation and chemotherapy. The expectation of successful immunotherapy rests on several important demonstrations. (1) Antigens are commonly observed in tumours which are not present in normal adult tissue. (2) The host is often capable of an immune response against its malignant neoplasm. (3) Immune competence of the host is related, albeit imperfectly, to prognosis. (4) Immunological resistance to tumour growth can be effected.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Fefer, A. (1974). Tumour immunotherapy. In: Handbook of Experimental Pharmacology (A. C. Sartorelli and D. G. Johns; eds.), 38 (Part 1), p. 528. (New York: Springer-Verlag)

    Google Scholar 

  2. McKhann, C. F. and Gunnarsson, A. (1974). Approaches to immunotherapy. Cancer, 34, 1521

    PubMed  Google Scholar 

  3. Hersh, E. M., Gutterman, J. U. and Mavligit, G. (1973). Immunotherapy of Cancer in Man. (Springfield, 111.: Charles C. Thomas)

    Google Scholar 

  4. Parker, C. W. (1973). The immunotherapy of cancer. Pharmacol. Rev., 25, 325

    PubMed  CAS  Google Scholar 

  5. Morton, D. L. (1972). Immunotherapy of cancer. Cancer, 30, 1647

    PubMed  CAS  Google Scholar 

  6. Prager, M. D. and Baechtel, F. S. (1973). Methods for modification of cancer cells to enhance their antigenicity. In: Methods in Cancer Research (H. Busch; ed.), 9, p. 339. (New York: Academic Press)

    Google Scholar 

  7. Prager, M. D. (1973). Immunological stimulation with modified cancer cells. Biomedicine, 18, 261

    PubMed  CAS  Google Scholar 

  8. Prager, M. D. (1975). Immune response to modified tumour cells. In: Cellular Membranes and Tumour Cell Behaviour, p. 523. (Baltimore: Williams and Wilkins)

    Google Scholar 

  9. Prager, M. D., Gordon, W. C. and Baechtel, F. S. (1976). Immunogenicity of modified tumour cells in syngenic hosts. Ann. N. Y. Acad. Sci., 276, 61

    PubMed  CAS  Google Scholar 

  10. Bekesi, J. G., St-Ameault, G. and Holland, J. F. (1971). Increase of leukemia L1210 immunogenicity by vibrio cholerae neuraminidase treatment. Cancer Res., 31, 2130

    PubMed  CAS  Google Scholar 

  11. Ray, P. K., Thakur, V. S. and Sundaram, K. (1975). Antitumor immunity. 1. Differential response of neuraminidase-treated and x-irradiated tumour vaccine. Eur. J. Cancer, 11, 1

    PubMed  CAS  Google Scholar 

  12. Martin, W. J., Wunderlich, J. R., Fletcher, F. and Inman, J. K. (1971). Enhanced immunogenicity of chemically-coated syngeneic tumor cells. Proc. Nat. Acad. Sci. USA, 68,469

    PubMed  CAS  Google Scholar 

  13. Prager, M. D., Hollinshead, A. C., Ribble, R. J. and Derr, I. (1973). Induction of immunity to a mouse lymphoma by multiple methods, including vaccination with soluble membrane fractions. J. Nat. Cancer Inst., 51, 1603

    PubMed  CAS  Google Scholar 

  14. Prager, M. D., Ribble, R. J. and Mehta, J. M. (1974). Aspects of the immunology of the tumor-host relationship and responsiveness to modified lymphoma cells. Recent Results Cancer Res., 47, 379

    Google Scholar 

  15. Prager, M. D. (1973). Vaccination and immunotherapy with chemically modified cancer cells. In:Unifying Concepts of Leukemia, (Bibliotheca Haematologica, 39) (R. M. Dutcher and L. Chieco-Bianchi; eds.), p. 706. (Basel: S. Karger)

    Google Scholar 

  16. Prager, M. D., Baechtel, F. S., Ribble, R. J., Ludden, C. M. and Mehta, J. M. (1974). Immunological stimulation with modified lymphoma cells in a minimally responsive tumour-host system. Cancer Res., 34, 3203

    PubMed  CAS  Google Scholar 

  17. Prager, M. D., Ludden, C. M., Mandy, W. J., Allison, J. P. and Kitto, G. B. (1975). Endotoxin-stimulated immune response to modified lymphoma cells. J. Nat. Cancer Inst., 54, 773

    PubMed  CAS  Google Scholar 

  18. Prager, M. D., Granatek, C. H. and Ludden, C. M. (1976). Syngeneic and allogeneic mouse lymphoma antisera: specificity, reaction with fetal antigen and protective capacity. Israel J. Med. Sci., 12, 325

    PubMed  CAS  Google Scholar 

  19. Baechtel, F. S. and Prager, M. D. (1977). Anti-thymocyte autoimmunity in BALB/c mice accompanying immunization to syngeneic lymphoma. J. Immunol 118,175

    PubMed  CAS  Google Scholar 

  20. Gordon, W. C. and Prager, M. D. (1977). Effector cell stimulation-inhibition of in vitro lymphoma cell DNA synthesis and correlation with in vivo anti-tumour response. Cancer Res, 37, 507.

    PubMed  CAS  Google Scholar 

  21. Coon, J. and Hunter, R. (1973). Selective induction of delayed hypersensitivity by a lipid conjugated protein antigen which is localized in thymus dependent lymphoid tissue. J. Immunol., 110, 183

    PubMed  CAS  Google Scholar 

  22. Dailey, M. O. and Hunter, R. L. (1974). The role of lipid in the induction of hapten-specific delayed hypersensitivity and contact sensitivity. J, Immunol, 112, 1526

    CAS  Google Scholar 

  23. Champlin, R. and Hunter, R. L. (1975). Studies on the composition of adjuvants which selectively enhance delayed-type hypersensitivity to lipid conjugated protein antigens. J. Immunol, 114, 76

    PubMed  CAS  Google Scholar 

  24. Coon, J. and Hunter, R. (1975). Properties of conjugated protein immunogens which selectively stimulate delayed-type hypersensitivity. J. Immunol, 114, 1518

    PubMed  CAS  Google Scholar 

  25. Parish, C. R. (1971). Immune response to chemically modified flagellin. I. Induction of antibody tolerance to flagellin by acetoacetylated derivatives of the protein. J. Exp. Med., 134, 1

    PubMed  CAS  Google Scholar 

  26. Parish, C. R. (1971). Immune response to chemically modified flagellin. II. Evidence for a fundamental relationship between humoral and cell-mediated immunity. J. Exp. Med., 134, 21

    PubMed  CAS  Google Scholar 

  27. Parish, C. R. (1972). Preferential induction of cell-mediated immunity by chemically modified sheep erythrocytes. Eur. J. Immunol, 2, 143

    PubMed  CAS  Google Scholar 

  28. Chao, H., Peiper, S. C., Aach R. D. and Parker, C. W. (1973). Introduction of cellular immunity to a chemically altered tumour antigen. J. Immunol, 111, 1800

    PubMed  CAS  Google Scholar 

  29. Levy, J. G., Whitney, R. B., Smith, A. G. and Panno, L. (1974). The relationship of immune status to the efficacy of immunotherapy in preventing tumour recurrence in mice. Br. J. Cancer, 30, 289

    PubMed  CAS  Google Scholar 

  30. Benjamini, E. and Scibienski, R. J. (1975). Immunochemical approaches to immunotherapy. Proc. XI Int. Cancer Cong., 1, 327

    Google Scholar 

  31. Thompson, K., Harris, M., Benjamini, E., Mitchell, G. and Noble, M. (1972). Cellular and humoral immunity: a distinction in antigenic recognition. Nature New Biol, 238, 20

    PubMed  CAS  Google Scholar 

  32. Hunter, R. L. and Strickland, F. (1975). Immunization with a lipid-conjugated membrane antigen to suppress growth of a fibrosarcoma induced by simian virus 40. J. Nat. Cancer Inst., 54, 1157

    PubMed  CAS  Google Scholar 

  33. Bekesi, J. G., St-Ameault, G., Walter, L. and Holland, J. F. (1972). Immunogenicity of leukemia L1210 cells after neuraminidase treatment. J. Nat. Cancer Inst., 49, 107

    PubMed  CAS  Google Scholar 

  34. Bekesi, J. G., Roboz, J. P., Walter, L. and Holland, J. F. (1974). Stimulation of specific immunity against cancer by neuraminidase-treated tumour cells. Behring Inst. Mitt., 55, 309

    CAS  Google Scholar 

  35. Simmons, R. L., Rios, A., Lundgren, G., Ray, P. K., McKhann, C. F. and Haywood, G. R. (1971). Immunospecific regression of methylcholanthrene fibrosarcoma using neuraminidase. Surgery, 70, 38

    PubMed  CAS  Google Scholar 

  36. Ray, P. K. and Simmons, R. L. (1973). Differential release of sialic acid from normal and malignant cells by vibrio cholerae neuraminidase or influenza virus neuraminidase. Cancer Res., 33, 936

    PubMed  CAS  Google Scholar 

  37. Sanford, B. H. and Codington, J. F. (1971). Further studies on the effect of neuraminidase on tumour cell transplantability. Tissue Antigens, 1, 153

    PubMed  CAS  Google Scholar 

  38. Hughes, R. C., Sanford, B. and Jeanioz, R. W. (1972). Regeneration of the surface glycoproteins of a transplantable mouse tumour cell after treatment with neuraminidase. Proc. Nat. Acad. Sci. U.S,A., 69, 942

    CAS  Google Scholar 

  39. Rosenberg, S. A. and Schwarz, S. (1974). Murine antibodies to a cryptic membrane antigen: possible explanation for neuraminidase-induced increase in cell immunogenicity. J. Nat. Cancer Inst., 52, 1151

    PubMed  CAS  Google Scholar 

  40. Simmons, R. L. and Rios, A. (1973). Comparative and combined effect of BCG and neuraminidase in experimental immunotherapy. Nat. Cancer Inst. Monogr., 39, 57

    PubMed  CAS  Google Scholar 

  41. Simmons, R. L. and Rios, A. (1974). Modification of immunogenicity in experimental immunotherapy and prophylaxis. Recent Results Cancer Res., 47, 370

    Google Scholar 

  42. Simmons, R. L. and Rios, A (1974). Immunospecific regression of methylcholanthrene fibrosarcoma with the use of neuraminidase. V. Quantitative aspects of the experimental immunotherapeutic model. Israel J. Med. Sci., 10, 925

    Google Scholar 

  43. Simmons, R. L. and Rios, A. (1974). Cell surface modification in the treatment of experimental cancer: neuraminidase or Concanavalin A. Cancer, 34, 1541

    PubMed  Google Scholar 

  44. Rios, A. and Simmons, R. L. (1974). Active specific immunotherapy of minimal residual tumour: excision plus neuraminidase-treated tumour cells. Int. J. Cancer, 13, 71

    PubMed  CAS  Google Scholar 

  45. Rios, A. and Simmons, R. L. (1973). Immunospecific regression of various syngeneic mouse tumors in response to neuraminidase-treated tumor cells. J. Nat. Cancer Inst., 51, 637

    PubMed  CAS  Google Scholar 

  46. Simmons, R. L. and Rios, A. (1973). Differential effect of neuraminidase on the immunogenicity of viral associated and private antigens of mammary carcinomas. J. Immunol, 111, 1820

    PubMed  CAS  Google Scholar 

  47. Simmons, R. L., Rios, A. and Trites, P. (1976). Modified tumor cells in the immunotherapy of solid mammary tumors. Med. Clin. N. Am., 60, 551

    PubMed  CAS  Google Scholar 

  48. Simmons, R. L. and Rios, A. (1972). Immunospecific regression of methylcholanthrene fibrosarcoma using neuraminidase. II. Intratumour injections of neuraminidase. Surgery, 71, 556

    PubMed  CAS  Google Scholar 

  49. Sparks, F. C. and Breeding, J. H. (1974). Tumor regression and enhancement resulting from immunotherapy with Bacillus Calmette-Guerin and neuraminidase. Cancer Res., 34, 3262

    PubMed  CAS  Google Scholar 

  50. Kollmorgen, G. M., Killion, J. J., Sansing, W. A., Cantrell, J. L., Bundren, J. C. and LeFever, A. V. (1976). Immunotherapy with neuraminidase-treated cells and Bacillus Calmette-Guerin. Surgery, 79, 202

    PubMed  CAS  Google Scholar 

  51. Kollmorgen, G. M., Sansing, W. A., Cantrell, J. L., Killion J. J. and Bundren, J. C. (1975). Treatment of murine lymphocytic leukemia with BCNU, VCN treated cells and BCG. In: Neoplasm Immunity: Theory and Application (R. Crispen; ed.), p. 27. (Chicago: ITR Press)

    Google Scholar 

  52. Sansing, W. A. and Kollmorgen, G. M. (1976). Humoral response to neuraminidase-treated tumour cells. J. Nat. Cancer Inst., 56, 1113

    PubMed  CAS  Google Scholar 

  53. LeFever, A. V., Killion, J. J. and Kollmorgen, G. M. (1976). Active immunotherapy of LI210 leukemia with neuraminidase-treated drug-resistant L1210 leukemia with neuraminidase-treated drug-resistant LI210 sublines. Cancer Immunol. Immunother. 1, 211

    Google Scholar 

  54. Albright, L., Madigan J. C., Gaston, M. R. and Houchens, D. P. (1975). Therapy in an intracerebral murine glioma model, using Bacillus Calmette-Guerin, neuraminidase-treated tumour cells, and l-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea. Cancer Res., 35, 658

    PubMed  CAS  Google Scholar 

  55. Lindenmann, J. (1974). Viruses as immunological adjuvants in cancer. Biochim. Biophys. Acta, 355, 49

    PubMed  CAS  Google Scholar 

  56. Koprowski, H., Love, R. and Koprowska, I. (1957). Enhancement of susceptibility to viruses in neoplastic tissues. Texas Rep. Biol. Med., 15, 559

    CAS  Google Scholar 

  57. Lindenmann, J. (1963). Viral oncolysis with host survival. Proc. Soc. Exp. Biol. Med., 113, 85

    PubMed  CAS  Google Scholar 

  58. Lindenmann, J. (1964). Immunity to transplantable tumors following viral oncolysis. I. Mechanism of immunity to Ehrlich ascites tumour. J. Immunol, 92, 912

    PubMed  CAS  Google Scholar 

  59. Lindenmann, J. and Klein, P. A. (1967). Viral oncolysis: increased immunogenicity of host ceU antigen associated with influenza virus. J. Exp. Med., 126, 93

    PubMed  CAS  Google Scholar 

  60. Boone, C., Blackman, K. and Brandschaft, P. (1971). Tumour immunity induced in mice with ceU-free homogenates of influenza virus-infected tumour cells. Nature (London), 231, 265

    CAS  Google Scholar 

  61. Griffith, I. P., Crook, N. E. and White, D. O. (1975). Protection of mice against cancer by immunization with membranes but not purified virions from virus infected cancer cells. Br. J. Cancer, 31, 603

    PubMed  CAS  Google Scholar 

  62. Haller, O. and Lindenmann, J. (1975). Host-cell antigen potentiated by incomplete growth cycle of influenza virus. J. Nat. Cancer Inst., 54, 459

    PubMed  CAS  Google Scholar 

  63. Plescia, O. J. (1969). The role of the carrier in antibody formation. Curr. Top. Microbiol. Immunol., 50, 78

    PubMed  CAS  Google Scholar 

  64. Mitchison, N. A. (1970). Immunologic approach to cancer. Transplant. Proc., 2, 92

    PubMed  CAS  Google Scholar 

  65. Bretscher, P. and Cohn, M. (1970). A theory of self-nonself discrimination. Science, 169, 1042

    PubMed  CAS  Google Scholar 

  66. Boone, C. W., Paranjpe, M., Orme, T. and Gillette, R. (1973). Virus-augmented tumor transplantation antigens—evidence for a helper antigen mechanism. Int. J. Cancer, 13, 543

    Google Scholar 

  67. Silagi, S. (1971). Modification of malignancy by 5-bromodeoxyuridine. In Vitro, 7, 105

    PubMed  CAS  Google Scholar 

  68. Silagi, S., Beju, D., Wrathall, J. and Deharven, E. (1972). Tumorigenicity, immunogenicity, and virus production in mouse melanoma cells treated with 5-bromodeoxyuridine. Proc. Nat. Acad. Sci., 69, 3443

    PubMed  CAS  Google Scholar 

  69. Silagi, S., Newcomb, E. W. and Weksler, M. E. (1974). Relationship of antigenicity of melanoma cells grown in 5-bromodeoxyuridine to reduced tumorigenicity. Cancer Res., 34, 100

    PubMed  CAS  Google Scholar 

  70. Silagi, S. (1976). Effects of 5-bromodeoxyuridine on tumorigenicity, immunogenicity, virus production, plasminogen activator, and melanogenesis of mouse melanoma cells. Int. Rev. Cytol, 45, 65

    PubMed  CAS  Google Scholar 

  71. Ishidate, M., Hashimoto, Y., Odashima, S. and Sudo, H. (1965). Studies on acquired transplantation resistance. I. Pretreatment of Donryu rat with attenuated Yoshida sarcoma cells. Gann, 56, 13

    PubMed  CAS  Google Scholar 

  72. Tsukagoshi, S. and Hashimoto, Y. (1973). Increased immunosensitivity in nitrogen mustard-resistant Yoshida sarcoma. Cancer Res., 33, 1038

    PubMed  CAS  Google Scholar 

  73. Mihich, E. (1969). Combined effects of chemotherapy and immunity against leukemia L1210 in DBA/2 mice. Cancer Res., 29, 848

    PubMed  CAS  Google Scholar 

  74. Mihich, E. (1969). Modification of tumour regression by immunologic means. Cancer Res., 29, 2345

    PubMed  CAS  Google Scholar 

  75. Mihich, E. and Kitano, M. (1971). Differences in the immunogenicity of leukemia L1210 sublines in DBA/2 mice. Cancer Res., 31, 1999

    Google Scholar 

  76. Kitano, M., Mihich, E. and Pressman, D. (1972). Antigenic differences between leukemia LI210 and a subline resistant to methylglyoxal-bis (guanylhydrazone). Cancer Res., 32, 181

    PubMed  CAS  Google Scholar 

  77. Bonmassar, E., Bonmassar, A., Vadlamudi, S. and Goldin, A. (1970). Immunological alteration of leukemic cells in vivo after treatment with an antitumor drug. Proc. Nat. Acad. Sci., 66, 1089

    PubMed  CAS  Google Scholar 

  78. Bonmassar, E., Bonmassar, A., Vadlamudi, S. and Goldin, A. (1972). Antigenic changes of L1210 leukemia in mice treated with 5-(3,3-dimethyl-l-triazeno) imidazole-4-carboxamide. Cancer Res., 32, 1446

    PubMed  CAS  Google Scholar 

  79. Nicolin, A., Vadlamudi, S. and Goldin, A. (1972). Antigenicity of L1210 leukemic sublines induced by drugs. Cancer Res., 32, 653

    PubMed  CAS  Google Scholar 

  80. Nicolin, A., Bini, A., Franco, P. and Goldin, A. (1974). Cell-mediated response to a mouse leukemic subline antigenically altered following drug treatment in vivo. Cancer Chemother. Rep., 58, 325

    CAS  Google Scholar 

  81. Fuji, H. and Mihich, E. (1975). Selection for high immunogenicity in drug-resistant sublines of murine lymphomas demonstrated by plaque assay. Cancer Res., 35, 946

    PubMed  CAS  Google Scholar 

  82. Nicolin, A., Bini, A., Coronetti, E. and Goldin, A. (1974). Cellular immune response to a drug-treated L5178Y lymphoma subline. Nature (London), 251, 654

    CAS  Google Scholar 

  83. Nicolin, A., Spreafico, F., Bonmassar, E. and Goldin, A. (1976). Antigenic changes of L5178Y lymphoma after treatment with 5-(3,3-dimethyl-l-triazeno) imidazole-4-carboxamide in vivo. J. Nat. Cancer Inst., 56, 89

    PubMed  CAS  Google Scholar 

  84. Bonmassar, E., Testorelli, C., Franco, P., Goldin, A. and Cudkowicz, G. (1975). Changes of the immunogenic properties of a radiation-induced mouse lymphoma following treatment with antitumor drugs. Cancer Res., 35, 1957

    PubMed  CAS  Google Scholar 

  85. Houchens, D. P., Bonmassar, E., Gaston, M. R., Kende, M. and Goldin, A. (1976). Drugmediated immunogenic changes of virus-induced leukemia in vivo. Cancer Res., 36, 1347

    CAS  Google Scholar 

  86. Killion, J. J. and Kollmorgen, G. M. (1976). Isolation of immunogenic tumour cells by cellaffinity chromatography. Nature (London), 259, 674

    CAS  Google Scholar 

  87. Reisfeld, R. A. and Kahan, B. D. (1970). Transplantation antigens. Adv. Immunol, 12, 117

    PubMed  CAS  Google Scholar 

  88. Kahan, B. D. (1973). Solubilization of allospecific and tumor-specific cell surface antigens. In: Methods Cancer Res., 9 (H. Busch; ed.), p. 283. (New York: Academic Press)

    Google Scholar 

  89. Oettgen, H. F., Old, L. J., McLean, E. P. and Carswell, E. A. (1968). Delayed hypersensitivity and transplantation immunity elicited by soluble antigens of chemically induced tumours in inbred guinea pigs. Nature (London), 220, 295

    CAS  Google Scholar 

  90. Holmes, E. C., Kahan, B. D. and Morton, D. L. (1970). Soluble tumour-specific transplantation antigens from methylcholanthrene induced guinea pig sarcomas. Cancer, 25, 373

    PubMed  CAS  Google Scholar 

  91. Pellis, N. R., Tom, B. H. and Kahan, B. D. (1974). Tumour-specific and allospecific immunogenicity of soluble extracts from chemically induced murine sarcomas. J. Immunol, 113, 708

    PubMed  CAS  Google Scholar 

  92. Pellis, N. R. and Kahan, B. D. (1975). Specific tumor immunity induced with soluble materials: restricted range of antigen dose and of challenge tumor load for immunoprotection. J. Immunol, 115,1717

    PubMed  CAS  Google Scholar 

  93. Irie, R. F., Kataoka, T. and Mitsui, H. (1970). Immunological studies on mouse mammary tumors. V. Chemical analysis of further purified tumor-specific antigen of mouse mammary tumour. Int. J. Cancer, 6, 304

    PubMed  CAS  Google Scholar 

  94. Takizawa, K., Yamamoto, T. and Mitsui, H. (1974). Transplantation resistance and potent antibody production induced in C3H/He mice against C3H/He mammary tumor by continuous infusion of solubilized antigen. Gann, 65, 541

    PubMed  CAS  Google Scholar 

  95. Meitzer, M. S., Leonard, E. J., Hardy, A. S. and Rapp, H. J. (1975). Protective tumour immunity induced by potassium chloride extracts of guinea pig hepatomas. J. Nat. Cancer Inst., 54, 1349

    Google Scholar 

  96. Meitzer, M. S., Leonard, E. J., Rapp, H. J. and Borsos, T. (1971). Tumour-specific antigen solubilized by hypertonic potassium chloride. J. Nat. Cancer Inst., 47, 703

    Google Scholar 

  97. Hollinshead, A., McCammon, J. R. and Yohn, D. S. (1972). Immunogenicity of a soluble membrane antigen from adenovirus-12 induced tumor cells demonstrated in inbred hamsters (PD-4). Can. J. Microbiol, 18, 1365

    PubMed  CAS  Google Scholar 

  98. Drapkin, M. S., Appella, E. and Law, L. W. (1974). Immunogenic properties of a soluble tumor-specific transplantation antigen induced by simian virus 40. J. Nat. Cancer Inst., 52, 259

    PubMed  CAS  Google Scholar 

  99. Law, L. W. and Appella, E. (1973). Immunogenic properties of solubilized tumour antigen from an RNA virus-transformed neoplasm. Nature (London), 243, 83

    CAS  Google Scholar 

  100. Baldwin, R. W. and Glaves, D. (1972). Solubilization of tumour-specific antigen from plasma membrane of an aminoazo dye-induced rat hepatoma. Clin. Exp. Immunol, 11, 51

    PubMed  CAS  Google Scholar 

  101. Baldwin, R. W., Harris, J. R. and Price, M. R. (1973). Fractionation of plasma membraneassociated tumour-specific antigen from an aminoazo dye-induced rat hepatoma. Int. J. Cancer, 11, 385

    PubMed  CAS  Google Scholar 

  102. Baldwin, R. W., Price, M. R. and Robins, R. A. (1973). Inhibition of hepatoma-immune lymph-node cell cytotoxicity by tumour-bearer serum and solubilized hepatoma antigen. Int. J. Cancer, 11, 527

    PubMed  CAS  Google Scholar 

  103. Baldwin, R. W., Embleton, M. J. and Moore, M. (1973). Immunogenicity of rat hepatoma membrane fractions. Br. J. Cancer, 28, 389

    PubMed  CAS  Google Scholar 

  104. Bonavida, B. and Zighelboim, J. (1974). Modulation of the immune response toward allograftsin vivo. I. Selective suppression of the development of cell-mediated immunity by soluble alloantigens. Cell Immunol, 13, 52

    PubMed  CAS  Google Scholar 

  105. Rao, V. S., Bonavida, B., Zighelboim, J. and Fahey, J. L. (1974). Preferential induction of serum blocking activity and enhancement of skin allograft by soluble alloantigen. Transplantation, 17, 568

    PubMed  CAS  Google Scholar 

  106. Rao, V. S. and Bonavida, B. (1976). Specific enhancement of tumor growth and depression of cell-mediated immunity following sensitization to soluble tumor antigens. Cancer Res., 36, 1384

    PubMed  CAS  Google Scholar 

  107. Benjamini, E., Theilin, G. H., Torten, M., Fong, S., Crow, S. and Henness, A. M. (1976). Tumour vaccines for immunotherapy of canine lymphosarcoma. Ann, N. Y. Acad. Sci., 277, 305

    CAS  Google Scholar 

  108. Pilch, Y. H., Fritze, D., Waldman, S. R. and Kern, D. H. (1975). Transfer of antitumor immunity by “immune” RNA. Curr. Top. Microbiol Immunol, 72, 157

    PubMed  CAS  Google Scholar 

  109. Fishman, M. (1961). Antibody formationin vitro. J. Exp. Med., 114, 837

    PubMed  CAS  Google Scholar 

  110. Alexander, P., Delorme, E. J., Hamilton, L. D. and Hall, J. G. (1967). Effect of nucleic acids from immune lymphocytes on rat sarcomata. Nature (London), 213, 569

    CAS  Google Scholar 

  111. Alexander, P., Delorme, E. J., Hamilton, L. D. and Hall, J. G. (1968). Stimulation of antitumor activity of the host with RNA from immune lymphocytes. In: O. J. Plescia and W. Braun (eds.) Nucleic Acids in Immunology, pp. 527–534. (Berlin-Heidelberg-New York: Springer-Verlag)

    Google Scholar 

  112. Londner, M. V., Morini, J. C., Font, M. T. and Rabasa, S. L. (1968). RNA-induced immunity against a rat sarcoma. Experientia, 24, 598

    PubMed  CAS  Google Scholar 

  113. Kennedy, C. T. C., Cater, D. B. and Hartveit, F. (1969). Protection of C3H mice against BP-8 tumor by RNA extracted from lymph nodes and spleens of specifically sensitized mice. Acta Pathol Microbiol Scand., 77, 196

    PubMed  CAS  Google Scholar 

  114. Rigby, P. G. (1969). Prolongation of survival of tumor-bearing animals by transfer of “immune” RNA with DEAE dextran. Nature (London), 221, 968

    CAS  Google Scholar 

  115. Kern, D. H., Drogemuller, C. R. and Pilch, Y. H. (1976). Mediation of immune responses to tumor antigensin vitro by immune RNA. Ann. N. Y. Acad. Sci., 276, 278

    PubMed  CAS  Google Scholar 

  116. Schlager, S. I. and Dray, S. (1975). Tumor regression at an untreated site during immunotherapy of an identical distant tumor. Proc. Nat. Acad. Sci. USA, 72, 3680

    PubMed  CAS  Google Scholar 

  117. Schlager, S. I., Paque, R. E. and Dray, S. (1975). Complete and apparently specific local tumor regression using syngeneic or xenogeneic “tumor-immune” RNA extracts. Cancer Res., 35, 1907

    PubMed  CAS  Google Scholar 

  118. Schlager, S. I. and Dray, S. (1976). Complete regression of a guinea pig hepatocarcinoma by immunotherapy with “tumor-immune” RNA or antibody to fibrin fragment. E. Israel J. Med. Sci., 12, 344

    CAS  Google Scholar 

  119. Pilch, Y. H., Fritz, D., deKernion, J. B., Ramming, K. P. and Kern, D. H. (1976). Immunotherapy of cancer with immune RNA in animal models and cancer patients. Ann. N. Y. Acad. Sci., 277, 592

    PubMed  CAS  Google Scholar 

  120. Deckers, P. J. and Pilch, Y. H. (1971). RNA-mediated transfer of tumor immunity—a new model for the immunotherapy of cancer. Cancer, 28, 1219

    PubMed  CAS  Google Scholar 

  121. Deckers, P. J., Wang, B. S. and Mannick, J. A. (1976). Immunotherapy of murine tumors with immune RNA. Ann. N. Y. Acad. Sci., 277, 575

    PubMed  CAS  Google Scholar 

  122. Fass, L. and Fefer, A. (1972). Factors related to therapeutic efficacy in adoptive chemoimmunotherapy of a Friend virus-induced lymphoma. Cancer Res., 32, 2427

    PubMed  CAS  Google Scholar 

  123. Berenson, J. R., Einstein, A. B., Jr. and Fefer, A. (1985). Syngeneic adoptive immunotherapy and chemoimmunotherapy of a Friend leukemia: requirement for T cells. J. Immunol, 115, 234

    Google Scholar 

  124. Fefer, A., Einstein, A. B., Cheever, M. A. and Berenson, J. R. (1976). Models for syngeneic adoptive chemoimmunotherapy of murine leukemias. Ann. N. Y. Acad. Sci., 276, 573

    PubMed  CAS  Google Scholar 

  125. Fefer, A., Einstein, A. B. and Cheever, M. A. (1976). Adoptive chemoimmunotherapy of cancer in animals: a review of results, principles, and problems. Ann. N. Y. Acad. Sci., 277, 492

    PubMed  CAS  Google Scholar 

  126. Fefer, A. (1971). Adoptive chemoimmunotherapy of a Moloney lymphoma. Int. J. Cancer, 8, 364

    PubMed  CAS  Google Scholar 

  127. Fefer, A. (1973). Treatment of a Moloney lymphoma with cyclophosphamide and H-2 incompatible spleen cells. Cancer Res., 33, 641

    PubMed  CAS  Google Scholar 

  128. Nicolin, A., Canti, G. and Goldin, A. (1974). Adoptive immunotherapy in BALB/c X DBA/2CrFi mice bearing an immunogenic subline of L1210 leukemia. Cancer Res., 34, 3044

    PubMed  CAS  Google Scholar 

  129. Takeichi, N., Kuzumaki, N., Kodama, T., Kobayashi, H. and Boone, C. W. (1976). Adoptive immunotherapy of a Gross virus producing lymphoma and a methylcholanthreneinduced fibrosarcoma in tolerant rats. Cancer Res., 36, 4039

    PubMed  CAS  Google Scholar 

  130. Fidler, I. J. (1974). Inhibition of pulmonary metastasis by intravenous injection of specifically activated macrophages. Cancer Res., 34, 1074

    PubMed  CAS  Google Scholar 

  131. Balme, R. H., Dockerty, M. B., Grindlay, J. H. and Litzow, T. J. (1962). The use of immune lymph in the treatment of mouse cancer. Minn. Med., 45, 892

    PubMed  CAS  Google Scholar 

  132. Delorme, E. J. and Alexander, P. (1964). Treatment of primary fibrosarcoma in the rat with immune lymphocjrtes. Lancet, ii, 117

    Google Scholar 

  133. Alexander, P. and Hall, J. G. (1970). The role of immunoblasts in host resistance and immunotherapy of primary sarcomata. Adv. Cancer Res., 13, 1

    PubMed  CAS  Google Scholar 

  134. Dullens, H. F. J., Kingma, E. J. and Otter, W. D. (1974). Immunotherapy with allogeneic hyperimmune peritoneal cells in a murine lymphoma system. Eur. J. Cancer, 10, 41

    PubMed  CAS  Google Scholar 

  135. Dullens, H. F. J. and Otter, W. D. (1974). Therapy with allogeneic immune peritoneal cells. Cancer Res., 34, 1726

    PubMed  CAS  Google Scholar 

  136. Dullens, H. F. J., Woutersen, R. A., de Weger, R. A. and Otter, W. D. (1974). Eradication of tumour cells by successive injections of allogeneic immune and hyperimmune peritoneal cells in a murine lymphoma system. Eur. J. Cancer, 10, 701

    PubMed  CAS  Google Scholar 

  137. Woodruff, M. F. A. and Boak, J. L. (1965). Inhibitory effect of pre-inmiunized CBA spleen cells on transplants of A-strain mouse mammary carcinoma in (CBA x A)Fi hybrid recipients. Br. J. Cancer, 19, 411

    PubMed  CAS  Google Scholar 

  138. Glynn, J. P., Halpem, B. L. and Fefer, A. (1969). An immunochemotherapeutic model for the treatment of a transplanted Moloney virus-induced lymphoma in mice. Cancer Res., 29, 515

    PubMed  CAS  Google Scholar 

  139. Kende, M., Keys, L. D., Gaston, M. and Goldin, A. (1975). Immunochemotherapy of transplantable Moloney leukemia with cyclophosphamide and allogeneic spleen lymphocytes and reversal of graft-versus-host disease with alloantiserum. Cancer Res., 35, 346

    PubMed  CAS  Google Scholar 

  140. Boranic, M. (1968). Transient graft-mw-host reaction in the treatment of leukemia in mice. J. Nat. Cancer Inst., 41, 421

    PubMed  CAS  Google Scholar 

  141. Bortin, M. M., Rimm, A. A., Rodey, G. E., Giller, R. H. and Saltzstein, E. C. (1974). Prolonged survival in long-passage AKR leukemia using chemotherapy, radiotherapy, and adoptive immunotherapy. Cancer Res., 34, 1851

    PubMed  CAS  Google Scholar 

  142. Chester, S. J., Esparza, A. R. and Albala, M. M. (1975). Graft versus leukemia without fatal graft-ümwf-host disease in AKR mice. Cancer Res., 35, 637

    PubMed  CAS  Google Scholar 

  143. Treves, A. J. and Cohen, I. R. (1973). Recruitment of effector T lymphocytes against a tumor allograft by T lymphocytes sensitizedin vitro. J. Nat. Cancer Inst., 51, 1919

    PubMed  CAS  Google Scholar 

  144. Treves, A. J., Cohen, I. R. and Feldman, M. (1975). Immunotherapy of lethal metastases by lymphocytes sensitized against tumor cells in vitro. J. Nat. Cancer Inst., 54, 111

    Google Scholar 

  145. Treves, A. J., Schechter, B., Cohen, I. R. and Feldman, M. (1976). Sensitization of T lymphocytes in vitro by syngeneic macrophages fed with tumor antigens. J. Immunol, 116, 1059

    PubMed  CAS  Google Scholar 

  146. Schechter, B., Treves, A. J. and Feldman, M. (1976). Specific cytotoxicity in vitro of lymphocytes sensitized in culture against tumor cells. J. Nat. Cancer Inst., 56, 975

    PubMed  CAS  Google Scholar 

  147. Lundak, R. L. and Raidt, D. J. (1973). Cellular immune response against tumor cells. I. In vitro immunization of allogeneic and syngeneic mouse spleen cell suspensions against DBA mastocytoma cells. Cell. Immunol., 9, 60

    PubMed  CAS  Google Scholar 

  148. Wagner, H. and Röllinghoff, M. (1973). Cell-mediated immunity in vitro against syngeneic mouse plasma tumour cells. Nature New Biol., 241, 53

    PubMed  CAS  Google Scholar 

  149. Wagner, H. and Röllinghoff, M. (1973). In vitro induction of tumor-specific immunity. I. Parameters of activation and cytotoxic reactivity of mouse lymphoid cells immunized in vitro against syngeneic and allogeneic plasma cell tumors. J. Exp. Med., 138, 1

    PubMed  CAS  Google Scholar 

  150. Kuperman, O., Fortner, G. W. and Lucas, Z. J. (1975). Immune response to a syngeneic mammary adenocarcinoma. 11. In vitro generation of cytotoxic lymphocytes. J. Immunol., 115, 1277

    PubMed  CAS  Google Scholar 

  151. Plata, F., Cerottini, J. C. and Brunner, K. T. (1975). Primary and secondary in vitro generation of cytolytic T lymphocytes in the murine sarcoma virus system. Eur. J. Immunol, 5, 111

    Google Scholar 

  152. Warnatz, H. and Scheiffarth, F. (1974). Cell-mediated immune response of in vitro sensitized lymphocytes to isogeneic methylcholanthrene-induced tumor cell lines. Transplantation, 18, 273

    PubMed  CAS  Google Scholar 

  153. Kali, M. A., Hellström, I. and Hellström, K. E. (1975). Different responses of lymphoid cells from tumor-bearing compared to tumor-immunized mice when sensitized to tumor specific antigens in vitro. Proc. Nat. Acad. Sci. U.S.A., 72, 5086

    Google Scholar 

  154. Kali, M. A. and Hellström, I. (1975). Specific stimulatory and cytotoxic effects of lymphocytes sensitized in vitro to either alloantigens or tumor antigens. J. Immunol., 114, 1083

    Google Scholar 

  155. Hellström, I. and Hellström, K. E. (1976). Specific sensitization of lymphocytes to tumor antigens by co-cultivation with peritoneal cells exposed to such antigens. Int. J. Cancer, 17, 748

    PubMed  Google Scholar 

  156. Carnaud, C., Ilfeld, D., Brook, I. and Trainin, N. (1973). Increased reactivity of mouse spleen cells sensitized in vitro against syngeneic tumor cells in the presence of a thymic humoral factor. J. Exp. Med., 138, 1521

    PubMed  CAS  Google Scholar 

  157. Small, M. and Trainin, N. (1975). Inhibition of syngeneic fibrosarcoma growth by lymphocytes sensitized on tumor cell monolayers in the presence of the thymic humoral factor. Int. J. Cancer, 15, 962

    PubMed  CAS  Google Scholar 

  158. Hericourt, J. and Richet, C. (1895). Traitement d’un Cas de sarcome par la serotherapie. C. R. Acad. Sci., 120, 948

    Google Scholar 

  159. Hericourt, J. and Richet, C. (1895). De la serotherapie dans le traitement du cancer. C. R. Acad. Sci., 121, 567

    Google Scholar 

  160. Motta, R.(1971). Passive immunotherapy ofleukemia and other cancer. J. Cancer Res., 14, 161

    CAS  Google Scholar 

  161. Asakuma, R. and Reif, A. E. (1968). The specificity of antilymphocyte sera to thymic, splenic, and leukemic lymphocytes. Cancer Res., 28, 707

    PubMed  CAS  Google Scholar 

  162. Reif, A. E. and Kim, C. H. (1971). Specificity of rabbit antisera against mouse leukaemias in vitro. Immunology, 20, 1087

    PubMed  CAS  Google Scholar 

  163. Koldovsky, P. and Svoboda, J. (1962). On the question of the role of heterologous tolerance in possibility to immunize against tumor antigen. Folia Biol, 8, 101

    CAS  Google Scholar 

  164. Levi, E. (1963). Preparation of an antiserum specific to a spontaneous mouse leukaemia after the induction of artificial immunological tolerance to normal mouse tissue. Nature (London), 199, 501

    CAS  Google Scholar 

  165. Levi, E. and Schechtman, A. M. (1963). The preparation in immunologically tolerant rabbits of antisera against the Ehrlich ascites tumor. Cancer Res., 23, 1566

    PubMed  CAS  Google Scholar 

  166. Trench, C. A. H., Gardner, P. and Green, C. A. (1963). Antibody production in tolerant rabbits to mouse lymphoma L-5178. Br. J. Cancer, 17, 287

    PubMed  CAS  Google Scholar 

  167. Levi, E., Golden, R., Zerubavel, R. and Fisher, J. (1966). The activity of tolerant antileukemia sera. I. In vivo effects. Cancer Res., 26, 659

    PubMed  CAS  Google Scholar 

  168. Motta, R. (1970). The passive immimotherapy of murine leukemia. I. The production of antisera against leukaemic antigens. Rev. Eur. Etudes Clin. Biol, 15, 161

    CAS  Google Scholar 

  169. Smith, P. J., Robinson, C. M. and Reif, A. E. (1974). Specificity of antüeukemia sera prepared by immunization with leukemia cells admixed with normal antigen-blocking sera. Cancer Res., 34, 169

    PubMed  CAS  Google Scholar 

  170. Weiner, R. S., Hubbard, J. D. and Mardiney, M. R. (1972). Production of tumor-specific antibody in the xenogeneic host: use of blocking antibody. J. Nat. Cancer Inst., 49, 1063

    PubMed  CAS  Google Scholar 

  171. Kaliss, N. (1970). Dynamics of immunologic enhancement. Transplant. Proc., 2, 59

    PubMed  CAS  Google Scholar 

  172. Amos, D. B., Cohen, I. and Klein, W. J. (1970). Mechanisms of immunologic enhancement. Transplant. Proc., 2, 68

    PubMed  CAS  Google Scholar 

  173. Snell, G. D. (1970). Immunologic enhancement. Surg. Gynecol. Obstet., 130, 1109

    PubMed  CAS  Google Scholar 

  174. Boy se, E. A., Old, L. J. and Stockert, E. (1962). Immunological enhancement of a leukaemia. Nature (London), 194, 1142

    Google Scholar 

  175. Möller, G. (1963). Studies on the mechanism of immunological enhancement of tumor homografts. II. Effect of isoantibodies on various tumor cells. J. Nat. Cancer Inst., 30, 1177

    PubMed  Google Scholar 

  176. Harris, T. N. and Harris, S. (1973). Fate of skin allografts in normal mice injected with antigraft strain globulin in relation to the IgGl and IgG2 class of the antibodies. Immunology, 25, 409

    PubMed  CAS  Google Scholar 

  177. Jansen, J. L. J., Koene, R. A. P., Kamp, G. J. V., Tamboer, W. P. M. and Wijdeveld, P. G. A. B. (1975). Isolation of pure IgG subclasses from mouse alloantiserum and their activity in enhancement and hyperacute rejection of skin allografts. J. Immunol, 115, 387

    PubMed  CAS  Google Scholar 

  178. Due, H. T., Kinsky, R. G., Kannelopoulos, J. and Voisin, G. A. (1975). Biologic properties of transplantation immune sera. IV. Influence of the course of immunization, dilution and complexing to antigen on enhancing activity of Ig classes. J. Immunol, 115, 1143

    Google Scholar 

  179. Chard, T., French, M. E. and Batchelor, J. R. (1967). Enhancement of the C57BL leukemia EL4 by Fab fragments of isoantibody. Transpianation, 5, 1266

    CAS  Google Scholar 

  180. Pressman, D. and Komgold, L. (1953). Thein vivo localization of anti-Wagner osteogenic sarcoma antibodies. Cancer, 6, 619

    PubMed  CAS  Google Scholar 

  181. Witz, I., Klein, G. and Pressman, D. (1969). Moloney lymphoma antibodies from mice; localization in spleens of Moloney lymphoma bearing mice. Proc. Soc. Exp. Biol Med., 130, 1102

    PubMed  CAS  Google Scholar 

  182. Reif, A. E. (1971). Studies on the localization of radiolabeled antibodies to a mouse myeloma protein. Cancer, 27, 1433

    PubMed  CAS  Google Scholar 

  183. Day, E. D. (1964). Vascular relationships of tumor and host. Prog. Exp. Tumor Res., 4, 57

    PubMed  CAS  Google Scholar 

  184. Izzo, M. J., Buchsbaum, D. J., and Bale, W. F. (1972). Localization of an labeled rat transplantation antibody in tumors carrying the corresponding antigen. Proc. Soc. Exp. Biol Med., 139, 1185

    PubMed  CAS  Google Scholar 

  185. Day, E. D., Planinsek, J. A. and Pressman, D. (1959). Localization in vivo of radioiodinated antirat-fibrin antibodies and radioiodinated rat fibrinogen in the Murphy rat lymphosarcoma and in other transplantable rat tumors. J. Nat. Cancer Inst., 22, 415

    Google Scholar 

  186. Bale, W. F., Spar, I. L. and Goodland, R. L. (1960). Experimental radiation therapy with I-carrying antibodies to fibrin. Cancer Res., 20, 1488

    PubMed  CAS  Google Scholar 

  187. Witz, I. P. (1977). Tumor bound immunoglobulins: in situ expressions of humoral immunity. Adv. Cancer Res., 25, 95

    PubMed  CAS  Google Scholar 

  188. Baldwin, R. W. and Robbins, R. A. (1975). Humoral factors abrogating cell-mediated immunity in the tumor-bearing host. Curr. Top. Microbiol Immunol, 72, 21

    PubMed  CAS  Google Scholar 

  189. Cooper, E. H., Bedford, A. J. and Kenny, T. E. (1975). Cell death in normal and malignant tissues. Adv. Cancer Res., 21, 59

    PubMed  CAS  Google Scholar 

  190. Gullino, P. M. (1975). Extracellular compartments of solid tumors. In: Cancer A Comprehensive Treatise, 3 (F. F. Becker; ed.), p. 327. (New York: Plenum Press)

    Google Scholar 

  191. Poole, A. R. (1973). Tumor lysosomal enzymes and invasive growth. In: Lysosomes in Biology and Pathology, 3 (J. T. Dingle; ed.), p. 303. (Amsterdam: North-Holland Publishing Co.)

    Google Scholar 

  192. Unanue, E. R. (1976). Secretory function of mononuclear phagocytes, J. Pathol, 83, 396

    CAS  Google Scholar 

  193. Rifkin, D. B., Loeb, J. N., Moore, G. and Reich, E. (1974). Properties of plasminogen activators formed by neoplastic human cell cultures. J. Exp. Med., 139, 1317

    PubMed  CAS  Google Scholar 

  194. Fell, H. B. and Dingle, J. T. (1963). Studies on the mode of action of excess of vitamin A6. Lysosomal protease and the degradation of cartilage matrix. Biochem. J., 87, 403

    PubMed  CAS  Google Scholar 

  195. Poole, A. R. (1970). The degradation of cartilage matrix by a lysosomal preparation, isolated from a malignant tumor, and its inhibition by an antiserum to this preparation. Histochem. J., 2, 431

    PubMed  CAS  Google Scholar 

  196. Gorer, P. A. and Amos, D. B. (1956). Passive immunity in mice against C57BL leukosis EL4 by means of isoimmune serum. Cancer Res., 16, 338

    PubMed  CAS  Google Scholar 

  197. Zighelboim, J., Bonavida, B. and Fahey, J. L. (1974). Antibody-mediated in vivo suppression of EL4 leukemia in a syngeneic host. J. Nat. Cancer Inst., 52, 879

    PubMed  CAS  Google Scholar 

  198. Alexander, P., Connell, D. I. and Mikulska, Z. B. (1966). Treatment of a murine leukemia with spleen cells or sera from allogeneic mice immunized against the tumor. Cancer Res., 26, 1508

    PubMed  CAS  Google Scholar 

  199. Shin, H. S., Pastemack, G. R., Economou, J. S., Johnson, R. L. and Hayden, M. L. (1976). Immunotherapy of cancer with antibody. Science, 194, 327

    PubMed  CAS  Google Scholar 

  200. Reif, A. E. and Kim, C.-A. I. (1969). Therapy of transplantable mouse leukaemias with antileukaemia sera. Nature (London), 223, 1377

    CAS  Google Scholar 

  201. Reif, A. E. and Kim, C.-A. I. (1971). Leukemia LI210 therapy trials with antileukemia serum and Bacillus Calmette-Guérin. Cancer Res., 31, 1606

    CAS  Google Scholar 

  202. Fefer, A. (1969). Immunotherapy and chemotherapy of Moloney sarcoma virus-induced tumors in mice. Cancer Res., 29, 2177

    PubMed  CAS  Google Scholar 

  203. Fefer, A. (1970). Immunotherapy of primary Moloney sarcoma virus-induced tumors. Int. J. Cancer, 5, 327

    PubMed  CAS  Google Scholar 

  204. Bansal, S. C. and Sjogren, H. O. (1971). “Unblocking” serum activity in vitro in the polyoma system may correlate with antitumour effects of antiserum in vivo. Nature New Biol, 233, 76

    PubMed  CAS  Google Scholar 

  205. Yutoku, M., Grossberg, A. L. and Pressman, D. (1974). Suppression ofin vivo growth of mouse myelomas by purified rabbit antibodies against mouse myeloma cells. J. Nat. Cancer Inst., 53, 201

    PubMed  CAS  Google Scholar 

  206. Mihaescu, G., Micu, N., Popp, I., Comisel, V. and Mihaescu, I. (1974). Treatment of ascites tumour with cytolytic serum obtained by double immunization. Neoplasma, 21, 297

    PubMed  CAS  Google Scholar 

  207. Vaage, J. (1976). Protective serum effects in tumor immunity. Israel J. Med. Sci., 12, 334

    PubMed  CAS  Google Scholar 

  208. Pearson, G. R., Redmon, L. W. and Pearson, J. W. (1973). Serochemotherapy against a Moloney virus-induced leukaemia. Cancer Res., 33, 1854

    PubMed  CAS  Google Scholar 

  209. Davies, D. A. L. (1974). The combined effect of drugs and tumor-specific antibodies in protection against a mouse lymphoma. Cancer Res., 34, 3040

    PubMed  CAS  Google Scholar 

  210. Davies, D. A. L. and O’Neill, G. J. (1973) In vivo and in vitro effects of tumour specific antibodies with chlorambucil. Br. J. Cancer, 28, (I), 285

    CAS  Google Scholar 

  211. Ghose, T., Cerini, M., Carter, M. and Nairn, R. C. (1967). Immunoradioactive agent against cancer. Br. Med. J., 1, 90

    PubMed  CAS  Google Scholar 

  212. Ghose, T. and Guclu, A. (1974). Cure of a mouse lymphoma with radio-iodinated antibody. Eur. J. Cancer, 10, 787

    PubMed  CAS  Google Scholar 

  213. Mathé, G., Loc, T. B. and Bernard, J. (1958). Effet sur la leucémie 1210 de la souris d’une combinaison par diazotation d’A-méthoptérine et de y-globulines de hamsters porteurs de cette leucémie par hétérogreffe. C. R. Acad. Sci., 246, 1626

    Google Scholar 

  214. Israels, L. G. and Linford, J. H. (1963). Some observations on the reactions of chlorambucil, azo-mustard (CB1414), and cyclophosphamide. Can. Cancer Conf., 5, 399

    PubMed  CAS  Google Scholar 

  215. Ghose, T., Path, M. R. C. and Nigam, S. P. (1972). Antibody as carrier of chlorambucil. Cancer, 29, 1398

    Google Scholar 

  216. Flechner, I. (1973). The cure and concomitant immunization of mice bearing Ehrlich ascites tumors by treatment with an antibody-alkylating agent complex. Eur. J. Cancer, 9, 741

    PubMed  CAS  Google Scholar 

  217. Ghose, T., Norvell, S. T., Guclu, A., Cameron, D., Bodurtha, A. and MacDonald, A. S. (1972). Immunochemotherapy of cancer with chlorambucil-carrying antibody. Br. Med. J., 3, 495

    PubMed  CAS  Google Scholar 

  218. Rubens, R. D. and Dulbecco, R. (1974). Augmentation of cytotoxic drug action by antibodies directed at cell surface. Nature (London), 248, 81

    CAS  Google Scholar 

  219. Moolten, F. L. and Cooperband, S. R. (1970). Selective destruction of target cells by diphtheria toxin conjugated to antibody directed against antigens on the cells. Science, 169, 68

    PubMed  CAS  Google Scholar 

  220. Moolten, F. L., Capparell, N. J. and Cooperband, S. J. (1972). Antitumour effects of antibody-diphtheria toxin conjugates: use of hapten-coated tumor cells as an antigenic target. J. Nat. Cancer Inst., 49, 1057

    PubMed  CAS  Google Scholar 

  221. Moolten, F. L., Capparell, N. J., Zajdel, S. H. and Cooperband, S. R. (1975). Antitumor effects of antibody-diphtheria toxin conjugates. II. Immunotherapy with conjugates directed against tumor antigens induced by Simian virus 40. J. Nat. Cancer Inst., 55, 473

    PubMed  CAS  Google Scholar 

  222. Linford, L. H., Froese, G., Berczi, I. and Israels, L. G. (1974). An alkylating agent-globulin conjugate with both alkylating and antibody activity. J. Nat. Cancer Inst., 52, 1665

    CAS  Google Scholar 

  223. Philpott, G. W., Bower, R. J. and Parker, C. W. (1973). Selective iodination and cytotoxicity of tumor cells with an antibody-enzyme conjugate. Surgery, 74, 51

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. M. D. Prager
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Royal Postgraduate Medical School, London, UK

    J. E. Castro

Rights and permissions

Reprints and permissions

Copyright information

© 1978 MTP Press Limited

About this chapter

Cite this chapter

Prager, M.D. (1978). Experimental specific immunotherapy. In: Castro, J.E. (eds) Immunological Aspects of Cancer. Springer, Dordrecht. https://doi.org/10.1007/978-94-010-9418-4_13

Download citation

  • DOI: https://doi.org/10.1007/978-94-010-9418-4_13

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-9420-7

  • Online ISBN: 978-94-010-9418-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation